Our Approach
Who We Are
Mwyngil is a biotechnology company founded in 2021. We grew out of a major scientific collaboration between Torrey Pines and DZNE (Deutsche Zentrum für Neurodegenerative Erkrankungen). From day one, we’ve built Mwyngil as a platform company—combining multiplex phenotypic assays with advanced computational approaches to modeling binding and selectivity to accelerate the translation of fundamental discoveries into clinical programs.
AI/ML R&D Platform
Our AI/ML R&D platform combines human domain expertise with state-of-the-art computational intelligence to transform early-stage drug discovery. Leveraging decades of proprietary experimental data, public resources, and advanced algorithms, the system guides decision-making across the full preclinical pipeline.
Biological Research Platform
Our biological research platform integrates advanced in vitro and in vivo technologies to uncover the mechanisms driving metabolic, inflammatory, and renal diseases. By combining human-relevant models with molecular and systems-level analysis, we generate high-quality translational data that accelerate candidate validation and clinical readiness.
Investors
Through collaboration with our global partners, we accelerate the development of next-generation therapies for obesity, chronic kidney disease, and inflammatory disorders — working together to bring meaningful impact to patients around the world.
